Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00004929
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003242
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00084812
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00084786
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00085579
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00085566
- Locations
- 🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00084773
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Biological Therapy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00002637
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006380
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
BMS-214662 in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004877
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States